- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03870165
Food First Approach to Stimulate Muscle Protein Synthesis in Healthy Adults (Salmon)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
On both infusion trials, participants will report to the laboratory at 0700 h after an overnight fast. Upon arrival to the lab, the participant will fill out a questionnaire and a baseline breath sample will be collected to determine 13CO2 enrichment by isotope ratio mass spectrometry. A Teflon catheter will be inserted into the antecubital vein for a baseline blood sample (t=-210) and then participants will receive priming doses of NaH13CO2 (2.35 µmol·kg-1), L-[1-13C]leucine (7.6 µmol·kg-1), and L-[ring-2H5]phenylalanine (2.0 µmol·kg-1). Subsequently, a continuous intravenous solution of L-[1-13C]leucine (0.10 µmol·kg-1·min-1) and L-[ring-2H5]phenylalanine (0.05 µmol·kg-1·min-1) will be initiated (t=-210) and maintained over the infusion trials. A second Teflon catheter will be inserted into a heated dorsal vein for repeated arterialized blood sampling and remained patent by a 0.9% saline drip. Breath samples and arterialized blood samples will be collected every 30 to 60 minutes during the postabsorptive and postprandial states. In the post-absorptive state of infusion trial 1, muscle biopsies will be collected at t=-150 and -30 min of infusion to determine basal-state myofibrillar protein synthesis rates, relative skeletal muscle amino acid transporter content, and anabolic-related signaling. In the subsequent cross-over trial only 1 muscle biopsy will be collected at t=-30 for Western blot analysis and postabsorptive myofibrillar protein-bound tracer enrichment. After collection of the resting muscle biopsy at t=-30 for both trials, the participants will perform resistance exercise that consists of 4 sets of 10-12 repetitions or to muscular failure at 65-70% of 1-RM for both leg press and leg extension exercise.
Immediately after the completion of the exercise bout, participants will ingest either 3.5 oz of Salmon fillet or a matched isolated amino acid and fat mixture (t=0). Completion of the meal will mark the start of the postprandial stage and additional muscle biopsies will be collected at t=120 and t=300.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Urbana, Illinois, United States, 61801
- Freer Hall
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 20-35 years
- Recreationally-active adults: ≥ 30 min of physical activity at moderate intensity ≥ 3 times per week
- English fluency
Exclusion Criteria:
- Smoking
- Known allergies to fish consumption
- Vegans
- Diagnosed GI tract diseases
- Arthritic conditions
- A history of neuromuscular problems
- Diagnosed cognitive impairments
- Recent (1 year) participation in amino acid tracer studies
- Predisposition to hypertrophic scarring or keloid formation
- Individuals on any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).
- High blood pressure (Systolic > 140 mm HG; Diastolic > 90 mm HG)
- Alcohol consumption >10 drinks per week
- Metabolic disorders (e.g., Metabolic Syndrome, diabetes, thyroid diseases)
- Consumption of thyroid, androgenic or other medications known to affect endocrine function
- Consumption of ergogenic-leves of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation
- Currently pregnant
- A suboptimal diet quality score as assessed by ASA24 dietary records
- Asthma
- Hypogonadism
- Cardiovascular disease, arrhythmias
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Salmon
After resistance exercise, participants will ingest 3.5 oz of salmon fillet (21g protein, 24g fat) cooked sous-vide.
|
Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture
Participants will ingest salmon immediately after resistance exercise
|
|
Experimental: Isolated mixture
After resistance exercise, participants will ingest an isolated amino acid and fatty acid mixture matched to the amino acid and fatty acid content of 3.5 oz salmon fillet.
|
Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture
Participants will ingest a mixture of isolated amino acids and fatty acids immediately after resistance exercise
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fractional synthetic rate of myofibrillar proteins
Time Frame: Postabsorptive for 3 hours, postprandial for 5 hours.
|
Myofibrillar protein synthesis rates will be assessed during the postabsorptive period for 3 hr and during the 5 hr after the ingestion of the experimental interventions.
This will allow us to assess the change from the postabsorptive to the postprandial period.
|
Postabsorptive for 3 hours, postprandial for 5 hours.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phosphorylation of muscle anabolic signaling
Time Frame: Baseline and at 2 and 5 hours after protein ingestion
|
Phosphorylation of anabolic signaling pathways will be assessed in the fasted state and at 2 and 5 hr after the ingestion of the experimental interventions.
|
Baseline and at 2 and 5 hours after protein ingestion
|
|
Exogenous rate of leucine appearance
Time Frame: 5 hour postprandial phase
|
Leucine oxidation rates will be assessed in the fasted state and at multiple time points in the postprandial phase.
|
5 hour postprandial phase
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nicholas A Burd, PhD, University of Illinois at Urbana-Champaign
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19293
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.